Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 469

Sort by

Sort Order Select

Journal Articles

Coagulation factor VIII: biological basis of emerging hemophilia A therapies

Benjamin J. Samelson-Jones, Bhavya S. Doshi, Lindsey A. George

Blood (2024) 144 (21): 2185–2197.

https://doi.org/10.1182/blood.2023023275

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic engineering of transfusable platelets with mRNA-lipid nanoparticles is compatible with blood banking practices

Colton Strong, Jerry Leung, Emma Kang, Katherine E. Badior, Madelaine Robertson, Nicolas Pereyra, Elyn M. Rowe, Amanda Wietrzny, Brenda Ma, Zechariah Noronha, Deaglan Arnold, Marco A. Ciufolini, Dana V. Devine, Eric Jan, Pieter R. Cullis, Christian J. Kastrup

Blood (2024) 144 (21): 2223–2236.

https://doi.org/10.1182/blood.2024024405

Published: 2024

Includes: Supplemental data

Journal Articles

Use of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviral gene therapy

Blood (2024) 144 (15): 1633–1645.

https://doi.org/10.1182/blood.2023023349

Published: 2024

Includes: Supplemental data

Journal Articles

How I Treat Sickle Cell Disease with Gene Therapy

Akshay Sharma

Blood blood.2024024519.

https://doi.org/10.1182/blood.2024024519

Published: 2024

Journal Articles

In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand

Blood (2024) 144 (9): 977–987.

https://doi.org/10.1182/blood.2024024523

Published: 2024

Includes: Supplemental data

Journal Articles

Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of the cell cycle

Blood (2024) 144 (7): 729–741.

https://doi.org/10.1182/blood.2023021426

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Blood (2024) 144 (6): 629–638.

https://doi.org/10.1182/blood.2023023419

Published: 2024

Includes: Supplemental data

Journal Articles

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

Eleftheria Kampouri, Elizabeth M. Krantz, Hu Xie, Sarah S. Ibrahimi, Erika S. Kiem, Mandeep K. Sekhon, Emily C. Liang, Andrew J. Cowan, Andrew Portuguese, Damian J. Green, Aya Albittar, Jennifer J. Huang, Jordan Gauthier, Ailyn C. Pérez-Osorio, Keith R. Jerome, Danielle M. Zerr, Michael J. Boeckh, Joshua A. Hill

Blood (2024) 144 (5): 490–495.

https://doi.org/10.1182/blood.2024024145

Published: 2024

Includes: Supplemental data

Journal Articles

SOX11 expression is restricted to EBV-negative Burkitt lymphoma and is associated with molecular genetic features

Blood (2024) 144 (2): 187–200.

https://doi.org/10.1182/blood.2023023242

Published: 2024

Includes: Supplemental data

Journal Articles

Integration of ζ -deficient CARs into the CD3 ζ gene conveys potent cytotoxicity in T and NK cells

Blood (2024) 143 (25): 2599–2611.

https://doi.org/10.1182/blood.2023020973

Published: 2024

Includes: Supplemental data

Journal Articles

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Blood (2024) 143 (25): 2654–2665.

https://doi.org/10.1182/blood.2023023301

Published: 2024

Includes: Supplemental data

Journal Articles

Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer

Paul Batty, Sylvia Fong, Matteo Franco, Choong-Ryoul Sihn, Laura L. Swystun, Saira Afzal, Lorianne Harpell, David Hurlbut, Abbey Pender, Cheng Su, Hauke Thomsen, Christopher Wilson, Loubna Youssar, Andrew Winterborn, Irene Gil-Farina, David Lillicrap

Blood (2024) 143 (23): 2373–2385.

https://doi.org/10.1182/blood.2023022589

Published: 2024

Includes: Supplemental data

Journal Articles

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

Magdi Elsallab, Moataz Ellithi, Matthew A. Lunning, Christopher D’Angelo, Jihyun Ma, Miguel-Angel Perales, Matthew Frigault, Marcela V. Maus

Blood (2024) 143 (20): 2099–2105.

https://doi.org/10.1182/blood.2024024166

Published: 2024

Includes: Supplemental data

Journal Articles

“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia

Edward J. Benz, Jr., Leslie E. Silberstein, Julie Panepinto

Blood (2024) 143 (11): 967–970.

https://doi.org/10.1182/blood.2023021598

Published: 2024

Journal Articles

Lactate administration improves laboratory parameters in murine models of iron overload

Wei Liu, Yue Wu, Huaiqing Wei, Juan Ma, Wenya Feng, Qiuyuan Yang, Shuping Zhang, Tomas Ganz, Sijin Liu

Blood (2024) 143 (11): 1045–1049.

https://doi.org/10.1182/blood.2023021695

Published: 2024

Includes: Supplemental data

Journal Articles

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study

Andrew D. Leavitt, Barbara A. Konkle, Kimo C. Stine, Nathan Visweshwar, Thomas J. Harrington, Adam Giermasz, Steven Arkin, Annie Fang, Frank Plonski, Anne Yver, Florence Ganne, Delphine Agathon, Maria de los Angeles Resa, Li-Jung Tseng, Gregory Di Russo, Bettina M. Cockroft, Liching Cao, Jeremy Rupon

Blood (2024) 143 (9): 796–806.

https://doi.org/10.1182/blood.2022018971

Published: 2024

Includes: Supplemental data

Journal Articles

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Blood (2024) 143 (6): 496–506.

https://doi.org/10.1182/blood.2023021243

Published: 2024

Includes: Supplemental data

Journal Articles

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Blood (2024) 143 (2): 139–151.

https://doi.org/10.1182/blood.2022018658

Published: 2024

Includes: Supplemental data

Journal Articles

Introduction to a review series on RNA therapeutics in hematology

Jason Gotlib

Blood (2023) 142 (19): 1577–1579.

https://doi.org/10.1182/blood.2023020910

Published: 2023

Journal Articles

Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments

David Adams, Vincent Algalarrondo, Andoni Echaniz-Laguna

Blood (2023) 142 (19): 1600–1612.

https://doi.org/10.1182/blood.2023019884

Published: 2023

NARROW

Coagulation factor VIII: biological basis of emerging hemophilia A therapies

Genetic engineering of transfusable platelets with mRNA-lipid nanoparticles is compatible with blood banking practices

Use of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviral gene therapy

How I Treat Sickle Cell Disease with Gene Therapy

In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand

Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of the cell cycle

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

SOX11 expression is restricted to EBV-negative Burkitt lymphoma and is associated with molecular genetic features

Integration of ζ -deficient CARs into the CD3 ζ gene conveys potent cytotoxicity in T and NK cells

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia

Lactate administration improves laboratory parameters in murine models of iron overload

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Introduction to a review series on RNA therapeutics in hematology

Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only